Anzeige
Mehr »
Login
Freitag, 21.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Drei Bohrgeräte, 23 Kilometer und die Vision, eine der 10 größten Goldminen Kanadas zu werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850501 | ISIN: US1101221083 | Ticker-Symbol: BRM
Tradegate
20.02.25
19:53 Uhr
52,56 Euro
-0,17
-0,32 %
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
BRISTOL-MYERS SQUIBB COMPANY Chart 1 Jahr
5-Tage-Chart
BRISTOL-MYERS SQUIBB COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
52,9053,0020.02.
52,9453,3120.02.
ACCESS Newswire
254 Leser
Artikel bewerten:
(1)

Rancho BioSciences, LLC: Rancho BioSciences Announces Bristol Myers Squibb Renews Membership for Phase 2 of the Single-Cell Data Science Consortium

Finanznachrichten News

SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 18, 2025 / Rancho BioSciences, the premier tech-enabled data science partner for biopharma, welcomes Bristol Myers Squibb (BMS) back for the 2nd phase of The Single-Cell Data Science Consortium. This continuing initiative aims to build on Phase 1's foundation, bringing together leading pharmaceutical companies with shared goals and needs in the realm of single-cell data.

The Single-Cell Data Science Consortium is a member-driven, pre-competitive collaboration to extract the value of single-cell data and establish a comprehensive data standard. This ambitious goal involves transforming vast amounts of public single-cell data into a unified standard that can significantly advance life sciences and drug discovery.

"BMS was one of the first members to join the consortium three years ago," said Julie Bryant, CEO of Rancho BioSciences. "Their continuing commitment is a testament to the quality and value this initiative is providing to its members."

Entering its fourth year, the consortium is on track to exceed the achievements of Phase 1. "Leveraging AI technologies and our team of PhD data science experts, we've delivered over 64 million professionally curated cells, nine atlases, as well as supporting data models and pipelines to date. This represents millions of dollars of value delivered to our members at a fraction of the cost and complication of attempting this alone. Phase 2 promises to deliver even more value to our members," added Bryant.

For more information about the Single-Cell Data Science Consortium and its initiatives, please visit Single-Cell Data Science - Data Science - Rancho BioSciences.

About Rancho BioSciences, LLC

Rancho BioSciences, LLC is a leading provider of tech enabled data science services, products and initiatives focused on life sciences. With a highly skilled team of PhD data scientists, curators, and bioinformaticians, Rancho BioSciences leverages data to accelerate medical research and enable new breakthroughs in treatment and care. Their mission, "Saving Lives Through Data," drives each project, helping clients harness the power of data to make life-saving discoveries. For more information about Rancho BioSciences, visit us at RanchoBioSciences.com or follow us on LinkedIn, YouTube and Facebook.

For media inquiries, please contact:
Julie Bryant
Phone: (760) 717-7881
Email: Julie.bryant@ranchobiosciences.com
Website: www.ranchobiosciences.com



.

SOURCE: Rancho BioSciences, LLC



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.